LONDON – Acacia Pharma Group plc reported positive results in a 1,200-patient phase III study of APD421, showing the anti-emetic reduced the relative risk of postoperative nausea and vomiting (PONV) by 22 percent when administered in combination with standard-of-care anti-emetics.